Acumen Pharmaceuticals (ABOS) Assets Average (2021 - 2026)

Acumen Pharmaceuticals has disclosed Assets Average across 6 years of filings, most recently posting $124.8 million for Q2 2026.

• In Q2 2026, Assets Average fell 33.67% year-over-year to $124.8 million; the TTM figure through Jun 2026 stood at $124.8 million (down 33.67% YoY), while the FY2025 annual figure was $180.9 million, down 34.11% from the prior year.
• Assets Average came in at $124.8 million for Q2 2026 at Acumen Pharmaceuticals, down from $128.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $305.5 million in Q1 2024 to a low of $124.8 million in Q2 2026.
• Average Assets Average over 5 years is $213.2 million, with a median of $211.7 million recorded in 2022.
• Year-over-year, Assets Average soared 61.49% in 2024 and plunged 47.61% in 2025.
• Over 5 years, Assets Average stood at $199.9 million in 2022, then surged by 49.18% to $298.2 million in 2023, then declined by 15.18% to $253.0 million in 2024, then plunged by 47.61% to $132.5 million in 2025, then fell by 5.82% to $124.8 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $124.8 million in Q2 2026, $128.2 million in Q1 2026, and $132.5 million in Q4 2025.